Company news

CSPC Pharmaceutical Group Limited news in 2025

CSPC Pharmaceutical Group Limited's news releases, calls and decks from 2025, newest first.

View company

Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer

October 20, 2025

Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session

October 18, 2025

The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration

September 11, 2025

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

July 30, 2025

Decks in 2025